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Abstract  
BACKGROUND Childhood acute lymphoblastic leukemia (ALL) survivors are at risk for 
impaired executive function, but it is unclear how to best screen for such impairment. We sought 
to determine 1) the reliability of neurocognitive assessment by performance-based testing versus 
parent report, and 2) how the measures relate to everyday function. 
METHODS 256 survivors of standard risk childhood B-ALL (mean age 13.9 years at 
evaluation) were evaluated for executive function with three performance-based measures 
(Wechsler Intelligence Scale for Children-IV (WISC-IV), Controlled Oral Word Association 
Test, and Conners’ Continuous Performance Test-II) and one parent-report measure (Behavior 
Rating Inventory of Executive Function (BRIEF)). The intra-class correlations between measures 
were assessed. The relation of the measures to the use of special education services and 
stimulants was analyzed with multivariate logistic regression. 
RESULTS The reliability between performance-based and parent-reported measures was poor, 
with the highest agreement observed between the WISC-IV Working Memory Index and the 
BRIEF-Working Memory Scale (kappa=0.143).  The use of special education services was 
significantly associated with impairment indicated by the BRIEF-WM Scale (odds ratio (OR) = 
5.94, 95% confidence interval (CI): 2.97, 12.78) and the WISC-IV WM Index (OR = 3.56, 95% 
CI: 1.61, 7.85).  Stimulant use was significantly associated with three BRIEF scales (WM, 
Inhibit, and Metacognition), but no performance-based measures. 
CONCLUSIONS Performance-based and parent-reported measures identified different ALL 
survivors with executive function impairment. The association between the parent-reported 
BRIEF measures and the use of special education and stimulants suggests that this instrument 
has an important value for surveillance. 
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BACKGROUND 
Over 90% of children with acute lymphoblastic leukemia (ALL) will be long-term 
survivors, 1 but modern therapy consisting of frequent intrathecal chemotherapy, intensive 
systemic chemotherapy, and, occasionally, cranial radiation, can exert neurotoxic effects.2 As a 
result, ALL survivors are at an increased risk for neurocognitive impairment as a late 
complication of their therapy. Affected cognitive domains include processing speed, attention, 
memory, fluency and cognitive organization.3 Each of these specific domains contributes to 
overall executive function, “the cognitive abilities necessary for goal-directed behavior and 
adaptation to a range of environmental changes and demands”.4 Difficulty with executive 
function in childhood cancer survivors has been linked to reduced emotional regulation,5 a 
decreased likelihood of living independently as adults, marrying, achieving higher education, and 
gaining employment.6-10  
Neurocognitive surveillance is recommended by the Children’s Oncology Group Long-
Term Follow-Up Guidelines for all childhood ALL survivors because of past neurotoxic 
therapy.11 The results of the assessment are used to determine the extent of neurocognitive 
evaluation necessary. Ultimately, results are used to determine the need for accommodations in 
school (e.g., extra time for work), special education services, and, when appropriate, other 
intervention strategies aimed at ameliorating cognitive function such as computer-based 
cognitive behavioral rehabilitation 12 or stimulants by prescription.13  Both neuropsychological 
testing and patient report (or proxy report) are used to screen for executive function, but it is 
unclear which approach is optimal.  
Historically, performance-based neuropsychological testing (usually by a psychologist) 
has been considered the “gold standard” measurement of executive function. Well-validated and 
	   7	  
standardized measures of executive function are routinely administered to patients to assess 
functioning, and identify children with deficits.14-19 However, performance-based testing requires 
significant professional resources and can be costly and time consuming. In addition, children 
may perform better in these test situations than “real world” settings.20 Therefore, 
neuropsychological tests may be limited in the ability to identify children with meaningful 
impairment or those at risk for not meeting age- and developmentally appropriate goals. 
Executive function assessed by patient/proxy report involves completing surveys 
regarding difficulty in real-world situations. The Behavior Rating Inventory of Executive 
Function, 21 a standardized parent-report measure, has been used to assess the executive function 
of pediatric patients with a variety of conditions.22 Parent-report measures such as the BRIEF 
offer several benefits. Scales and questionnaires can be mailed to respondents, require a limited 
amount of training to administer and score, and capture the real-world manifestation of functions 
such as working memory and task initiation. However, there is concern that anxiety about their 
child’s illness may alter parents’ assessment of their child’s executive function, as suggested by 
increased levels of reported impairment reported by parents compared with teachers.23 Another 
concern regarding parent report is reduced expectations of child’s performance and function, 
resulting in deflated reporting of impairment.24  
Further research is needed to determine how to best screen for executive function in 
survivors of childhood ALL as it relates to meaningful impact on everyday life. We had a unique 
opportunity to address this question in a large patient sample from a multi-site long-term follow-
up study of ALL patients treated without cranial radiation. In this study, we determined the 
reliability between performance-based and parent-reported measures of executive function, and 
evaluated how some dimensions of executive function, specifically working memory, fluency, 
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and impulse control measured by the two different approaches, relate to the use of special 
education services and stimulants.  
METHODS 
Study Population 
Included in this study are 256 childhood ALL patients who were enrolled in the 
Children’s Oncology Group clinical trial protocols 1922 and 1952, which were open March 1993 
- August 1995 and May 1996 - February 2000, respectively. Patients were eligible for the current 
study if they were diagnosed at one of the 22 designated institutions, were in first remission, and 
were 6-16.99 years of age at the time of their executive function evaluation. Other inclusion 
criteria included no history of central nervous system leukemia, no history of cranial radiation, 
one year or longer since cessation of therapy, no history of pre-existing developmental disorders 
(e.g., Down Syndrome, developmental delay), and no history of very low birth weight (<1500 
grams). This study methodology has been previously described.25-27 The age restriction 
corresponds to the validated age ranges of the standardized neuropsychological instruments used 
in the executive functioning evaluation. Informed consent and assent were obtained for all study 
participants. The institutional review boards of all participating institutions approved the study 
procedures and documents. 
Data Collection 
Parents of the participating childhood ALL patients completed a questionnaire about the 
demographic characteristics and medical history of their children. Parents were asked about their 
marital status, education, and income. This questionnaire confirmed that the child was 
developing normally before the ALL diagnosis as an additional verification of eligibility for this 
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study. In addition, parents provided information on their child’s neurologic events, use of special 
education services, and psychotropic drug use during and after ALL therapy. 
The patients underwent a comprehensive, half-day, neurocognitive assessment supervised 
by a licensed psychologist. This evaluation was conducted at no cost to the patients. The 
evaluation included, among others, three performance-based tests: the Wechsler Intelligence 
Scale for Children (WISC-IV), the Controlled Oral Word Association Test (COWAT), and the 
Conners’ Continuous Performance Test (CPT II).  In addition, parents of patients completed the 
Behavior Rating Inventory of Executive Function (BRIEF), a standardized parent-report measure 
(Table 1).  
 Table 4 displays impairment categories based on validation studies of these instruments	  16	  
21, 28, 29 
The WISC-IV: Performance-Based 
Patients were asked to perform two tasks from the WISC-IV,	  28 Digit Span and Letter-
Number Sequencing, which comprise the Working Memory Index. Digit span is a measure of 
attention and working memory and requires patients to listen to and then repeat series of 
numbers of increasing length forwards and then backwards.28 Letter number sequencing 
measures attention and working memory. Children listen to a series of letters and numbers and 
have to reorganize the numbers in numerical order followed by the letters in alphabetical order.28 
The COWAT: Performance-Based 
This test is a measure of verbal fluency as measured by an individual’s ability to generate 
words beginning with a specific letter. 29 COWAT performance is involves dimensions of 
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executive function such as cognitive flexibility, strategy utilization, suppression of interference 
and response inhibition, and it has also been proposed to involve the working memory processes 
as well. 29 	  
The CPT-II V.5: Performance-Based 
The CPT-II 16 is administered on a computer. Patients are required to press a key as 
quickly as possible in response to target letters presented on the computer screen or to refrain 
from pressing the key when non-target letters are presented. It measures attention, impulse 
control and reaction time. The subscale “Total Commission Errors” measures impulse control, 
and “HIT Reaction Time” measures information processing efficiency.	  16  
The BRIEF: Parent-Reported 
The BRIEF, 21 contains 86 items comprising eight scales regarding inhibitory control, 
ability to shift from one task to another, emotional control, initiation of activity, working 
memory, planning/organizing, and work-checking habits.	  21  
Three BRIEF subscales, and one composite scale were used to measure executive 
function in this study. These subscales included Working Memory, a 10-item scale; Initiate, an 
8-item scale used as a measure of fluency; and Inhibit, a 10-item scale used as a measure of 
impulse control. The Metacognition Index reflects an individual’s ability to initiate activity, to 
sustain working memory, and to organize one’s materials and environment, among others. 21 
Statistical Analyses 
Patient characteristics such as age, sex, and history of ALL therapy were summarized as 
appropriate. 
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Reliability of parent-reported as compared to performance-based measures of impaired 
functioning was examined using Cohen’s kappa, a measure of inter-rater agreement. 
Multivariate logistic regression models were used to examine the relationship between 
performance-based measures of executive function, parent-reported impairment, and patient’s 
use of special education services and/or stimulants, adjusting for time since diagnosis, sex and 
race. Additionally, a backward stepwise logistic regression model was utilized to identify factors 
associated with a single outcome measure termed “everyday impairment,” a combined measure 
of a positive history of special education services and/or stimulants.  
All analyses were conducted using the software package SAS (version 9.3, Cary, North 
Carolina).  
Results 
Demographic and Clinical Characteristics 
The 256 childhood ALL patients included in this study had a mean age of 12.5 years (SD 
= 2.4, median = 13) at the time of evaluation, and were on average about 9.19 years post 
diagnosis. There were slightly more females (53.0%, n = 136) than males (47.0%, n = 120). Of 
note, only one percent of the patients reported receiving special education services before 
treatment, as compared to 6.8% during treatment and 20.7% after treatment (p <0.001) (Table 2).  
Normative data from the general population for the WISC-IV, the COWAT, the CPT-II 
and the BRIEF were used to categorize impaired scores for each test or subscale. Statistically 
significant frequencies of impairment greater than the standard population were observed for the 
COWAT (p = 0.001), the BRIEF Working Memory subscale (p = 0.005), the BRIEF Initiate 
subscale (p = 0.01), and the BRIEF Metacognition Index (p = 0.04). Conversely, statistically 
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significantly lower frequencies of impairment were observed for the CPT-II Commissions and 
Omissions subscales (p < 0.001) (Table 3).	  	  
Impairment Classification According to Performance-Based Testing vs. Parent-Reported 
Measures 
Reliability between impairment classified by performance-based testing versus parent-
reported measures was assessed using Cohen’s Kappa (Table 4). Of all the performance-based 
and the corresponding parent-reported pairs of executive function measures tested (n=7) only 
three pairs showed statistically significant agreement: the WISC-IV Working Memory Index and 
the BRIEF-Working Memory (kappa = 0.14), the WISC-IV Letter-Number Sequencing and the 
BRIEF-Working Memory (kappa = 0.12), and the Controlled Oral Word Association Test and 
the BRIEF Initiate (kappa=0.16). Even for these three pairs, the kappa values were close to 0, 
indicating poor reliability between the two different approaches.   
Association between Impaired Cognition and Reported Use of Special Education Services 
The relation between impaired cognition and reported use of special education services 
was assessed using multivariate logistic regression models, adjusting for age at evaluation (in 
years), gender, and race (white vs. non-white). Of the performance-based measures, impairment 
indicated by the WISC-IV Working Memory Index (odds ratio (OR) = 3.56; 95% confidence 
interval (CI): 1.61, 7.85; p=0.002) and Digit Span (OR = 3.99; 95%CI: 2.08, 7.65; p < 0.001) 
scales as well as the COWAT (OR = 3.70; 95%CI: 1.89, 7.26; p < 0.001) were found to be 
significantly associated with an increased likelihood of using special education services (Table 
5). Impairment on three of the four BRIEF subscales was also significantly associated with the 
same outcome: Working Memory (OR = 5.94; 95%CI: 2.76, 12.78; p < 0.001), Inhibit (OR = 
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3.89; 95%CI: 1.59, 9.50; p = 0.003), and the Metacognition Index (OR = 3.80; 95%CI: 1.20, 
8.57; p = 0.001). 
Of the 60 patients receiving special education services after treatment, 21 (35.0%) were 
found to be clinically impaired based on the parent-report BRIEF, while only 15 (25.0%) were 
considered clinically impaired based on the performance-based WISC-IV Working Memory 
Index. Forty percent of these individuals (n = 24) were not identified as having impairment by 
either approach (i.e., performance-based or parent-reported measures) (Figure 1). 
Association between Impaired Cognition and Reported Use of Stimulants 
Impairment identified through performance-based measures was not associated with 
reported use of stimulants in this study population. In contrast, patients who were considered 
impaired based on one of the following three parent-reported scales from the BRIEF were 
significantly more likely to use stimulants: Working Memory (OR = 7.16; 95% CI 2.97, 20.28; p 
< 0.001), Inhibit (OR = 5.21; 95% CI 1.81, 14.98; p= 0.002), and the Metacognition Index (OR = 
4.88; 95% CI 1.77, 13.40; p= 0.002) (Table 5). 
Of the 23 patients who reported using stimulants, 12 (52.2%) were considered clinically 
impaired based on parent-reported BRIEF, and only 2 (8.7%) were identified as having clinically 
significant impairment based on the performance-based WISC-IV Working Memory Index 
(Figure 2). 
Discussion 
In this large cross-sectional study of childhood ALL survivors, we examined the utility of 
the BRIEF, a standardized parent-report instrument, as compared to performance-based measures 
to screen for executive function. Our analysis revealed that there is little concordance between 
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these two testing approaches as indicated by low kappa values. Both the performance-based and 
parent-reported measures were significantly associated with the use of special education services 
after adjusting for years since diagnosis, sex and race. However, the magnitude of association 
was larger for the parent-reported BRIEF Working Memory, Inhibit and Metacognition scales. 
For stimulant use, only parent-reported scales showed significant association. Our results suggest 
that parent report and performance based testing are complementary in identifying at risk 
patients. Parent-reported BRIEF scales identified more patients with executive function 
impairment who manifested as needing special education services and/or stimulants. If resources 
or psychological expertise is limited, the BRIEF is a useful and valuable instrument for 
surveillance in this population. 
The current study not only examines concordance and discordance between two testing 
methodologies, but also considers the application of these tests in terms of ecological validity. 
Additionally, the study included a relatively large number of childhood ALL patients who were 
treated with contemporary regimens, and had availability of high quality data on both 
performance-based and parent-reported measures. Due to the size of the study population, there 
was also the ability to examine and control for multiple potential confounders in the analyses. 
Consistent with studies in other populations,20 scores on the parent-reported measures in 
this ALL population were significantly different from the standard normative population, 
reflecting more impairment in this group. Our results also indicate that parents rated their 
children as displaying more impairment than suggested by results of performance-based 
measures.  Parents may be reporting higher levels of impairment, as their responses are based on 
continual observations of their child’s behavior in a real life setting, as compared to 
performance-based measures, which occur in a structured environment, or “ideal” conditions. 
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Others have hypothesized that parental expectations of “normal behavior” may be altered as a 
result of their child’s disease and the trauma associated with it; however, our study indicates that 
they may be even more sensitive to deficits in their children.  
Current findings indicate that performance-based measures were only significantly 
associated with reported use of special education services only, while the parent-reported BRIEF 
was associated with the use of both special education services and stimulants. Our findings 
differed from previous reports. Krull et al. compared the parent-reported Childhood Symptom 
Inventory to a range of performance-based neuropsychological tests in 240 survivors of 
childhood cancer.	  30 This report concluded that the parent-report assessment was inferior, but this 
instrument was primarily designed to measure emotion and behavior. Furthermore, the two 
assessment approaches were compared to achievement scores from the clinical testing 
environment, instead of everyday function. Howarth et al. studied the utility of the BRIEF in 
detecting working memory problems among 50 childhood brain tumor survivors.	  20 The results 
of this study similarly showed only modest correlations between parent-reported impairment and 
performance-based impairment, but in this population, the BRIEF under-classified the number of 
patients with working memory impairment. This study was limited in that it only examined one 
aspect of executive function, working memory, which may be disproportionately affected in 
children who are treated with conformal radiation therapy, as compared to our study sample. 
In a study of 199 children with NF1, functional impairment as defined by parent report on 
the BRIEF, detected different children than were detected as impaired by cognitive testing31. As 
in the current study, there is support that extrapolating real life impairment from performance-
based tests may has its limitations. 
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Our results do not support a gold standard strategy for the measurement of executive 
function in childhood ALL survivors. The performance-based and parent-reported measures 
identified different patients as impaired, with minimal overlap. The value of the parent-reported 
BRIEF was confirmed, as it was significantly associated with the use of special education 
services and stimulants in survivors. Given the considerable cost (often not reimbursed by 
insurance), time, and professional expertise needed for traditional neuropsychological testing, 
one strategy could be to use the BRIEF for routine surveillance in patients with a history of 
neurotoxic treatment exposures who do not complain of acute difficulties. Children with 
evidence of impairment on the BRIEF could then undergo follow-up performance-based 
neuropsychological testing for a more complete evaluation. Conversely, in settings where 
performance-based measures are readily available, there is independent added benefit to 
additionally requesting completion of the BRIEF as it has been indicated as an important 
surveillance tool that may indicate the need for more comprehensive neuropsychological testing. 
We acknowledge several limitations. First, this study employed a cross-sectional design, 
which made it infeasible to examine any changes in parent-reported executive function 
impairment over time. However, our primary focus was to compare two approaches for 
evaluation at a singular point in time, so for the purposes of this analysis, a measurement of 
change was not required. Additionally we recognize that stimulant use may alter the results of 
performance-based testing, as children who are impaired may fall into normal ranges due to the 
effects of the medications. However, the literature has suggested that stimulants are not as 
effective in cancer survivors, and thus performance-based testing should still indicate impairment 
for many of those taking stimulants.32 Finally, the use of special education services and 
stimulants are only two measures of everyday function. Some have argued that factors such as 
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socioeconomic status or parental education may effect who gets referred for these specialized 
services, with children of parents with higher education or higher SES having a higher rate of 
referral. Our data did not show any significant associations between SES nor parental education 
with the reported use of special education services or use of stimulants. Other important ones that 
were not available in our study include attainment of goal target scores on state administered 
tests of achievement, eventual highest level of educational achievement, future income, and later 
ability to live independently. Finally, we acknowledge that special education and stimulant 
history are meant as proxies for clinically important impairment. However, though parental 
education and advocacy can also affect referral for these services/therapies, there was not a 
significant relationship between income or parental education level and the use of special 
education services or stimulants.  
In a population at high risk for cognitive impairment, such as childhood ALL survivors, 
there is a strong need for a feasible and ecologically valid form of surveillance. The lack of 
concordance between the parent-reported and performance-based measures highlights the 
complexity of evaluating domains of executive function, and illustrates the value of 
comprehensive testing. When resources are more limited, our results suggest that the parent-
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Table 1: Summary of Standardized Tests Used to Measure Executive Function 
 
Measure (with subscales as applicable) Method of Assessment Construct Measured 
Wechsler Intelligence Scale for Children-IV  
Working Memory Index  










Controlled Oral Word Association Test Performance Initiation/Fluency 
Conners’ Continuous Performance Test-II  
Omissions  
Commissions 









Behavior Rating Inventory of Executive 
Function  
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Table 2: Demographic Characteristics of Participants (n=256) 
Column1 Mean (SD) or N (%) 
Age at Diagnosis (years) 3.90 (1.65) 
Elapsed time between diagnosis and 
evaluation (years) 
9.19 (1.37) 
Age at Evaluation (years) 12.5 (2.44) 
Sex  (n, %)  
Female 136 (53%) 
Male 120 (47%) 
Race/ethnicity   
White, non-Hispanic 207 (82%) 
Non-white 44 (18%) 
Stimulant Use After Treatment  23 (9.0%) 
Special Education Services  
Before Treatment 3 (1.2%) 
During Treatment 17 (6.8%) 
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Table 3: Overall Neuropsychological Performance on Performance-Based and Parent-Report 
Instruments 
 Normative Standardized 
Population 
Study Sample P-value 
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Table 4: Kappa Values for Reliability between Parent-Reported and Performance-Based 
Measures 




Performance Based Tests Working Memory Initiate Inhibit Metacognition 
Index 
P-value 
WISC-IVa Working Memory 
Index 
0.15 nab na na 0.02 
WISC-IV Letter-Number 
Sequencing 
0.11 na na na 0.05 
WISC-IV Digit Span 0.12 na na na 0.08 
Controlled Oral Word 
Association 
na 0.16 na na 0.007 
CPT-IIc Commission na na -0.005 na 0.47 
CPT-II Hit Reaction Time na na na 0.02 0.36 
CPT-II Omission na na na 0.002 0.49 
aWISC-IV: Wechsler Intelligence Scale for Children IV 
bna: not applicable 
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Table 5: Relation of Performance-Based and Parent-Reported Measures of Executive Function to 
Reported Use of Special Education Services and Stimulants* 
  History of Special Education 
Services 
History of Stimulant Use 
 
Measure Method of 
Assessment 
OR 95% CI P-value  OR 95% CI P-value 
WISC-IVa Working 
Memory Index 
Performance 3.56 (1.61,7.85) 0.002 1.74 (0.38, 9.68) 0.47 
WISC-IVa Digit Span Performance 3.99 (2.08, 7.65) <0.001 1.51 (0.59,3.96) 0.38 
Controlled Oral Word 
Association Test 
Performance 3.70 (1.89, 7.26) <0.001 1.39 (0.55,3.48) 0.49 
BRIEFc Working Memory Parent 5.94 (2.76, 
12.78) 
<0.001 7.16 (2.97, 20.28) <0.001 
BRIEFc Inhibit Parent 3.89 (1.59, 9.50) 0.003 5.21 (1.81, 14.98) 0.002 
BRIEFc Metacognition 
Index 
Parent 3.80 (1.20, 8.57) 0.0012 4.88 (1.77, 13.40) 0.002 
*Results based on multiple logistic regressions adjusted for time since diagnosis, gender and race 
aWISC-IV: Wechsler Intelligence Scale for Children IV 
b ns: not significant 











	   28	  
Figure 1: Impairment Detected by the BRIEF Working Memory Index and the WISC-IV Working 





* Numbers indicated the number of children in each category (eg: “28” in the Receives Special Education 
Services indicates that 28 children receive special education services, but did not have impairment 
indicated on either instrument; “17” indicates that 17 children receive special education services, and also 
were considered impaired on the BRIEF working memory index) 
aBehavior Rating Inventory of Executive Function (Parent-Report) 
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Figure 2: Impairment Detected by the BRIEF Working Memory Index and the WISC-IV Working 
Memory Index as Compared to Reported Stimulant Use
 
 
* Numbers indicated the number of children in each category (eg: “20” in Reported Stimulant Use 
indicates that 20 children use stimulants, but did not have impairment indicated on either instrument; “12” 
indicates that 12 children receive special education services, and also were considered impaired on the 
BRIEF working memory index) 
aBehavior Rating Inventory of Executive Function (Parent-Report) 
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